$PHCI
Panamera Holdings Corp

2020 Q2 Form 10-K Financial Statement

#000164033420002680 Filed on October 29, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q3 2019
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.00K $10.00K $30.00K
YoY Change 0.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.238K $10.00K $26.81K
YoY Change 15.4% -10.62%
Operating Profit -$5.238K -$26.81K
YoY Change 15.4%
Interest Expense $1.217K $0.00 $3.504K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.217K -$3.504K
YoY Change 33.59%
Pretax Income -$6.455K -$10.00K -$30.32K
YoY Change 18.44% 0.0% 1.06%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.455K -$10.00K -$30.32K
YoY Change 18.44% 0.0% 1.06%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 -$1.668K
COMMON SHARES
Basic Shares Outstanding 17.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q3 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00 $0.00
YoY Change
Cash & Equivalents $3.174K $671.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.174K $671.00 $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$3.174K $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.174K $671.00 $0.00
Total Long-Term Assets -$3.174K $0.00 $0.00
Total Assets $0.00 $671.00 $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.00K $0.00 $0.00
YoY Change -100.0% -100.0%
Accrued Expenses $10.00K $10.00K $10.00K
YoY Change 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $80.00K $80.00K
YoY Change 25.0% 60.0% 60.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $120.0K $90.64K $90.00K
YoY Change 33.33% 51.07% 50.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $120.0K $90.64K $90.00K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $120.0K $90.64K $90.00K
YoY Change 33.33% 51.07% 50.0%
SHAREHOLDERS EQUITY
Retained Earnings -$237.5K
YoY Change
Common Stock $147.5K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$114.9K -$89.97K -$90.00K
YoY Change
Total Liabilities & Shareholders Equity $0.00 $671.00 $0.00
YoY Change

Cashflow Statement

Concept 2020 Q2 2019 Q3 2019
OPERATING ACTIVITIES
Net Income -$6.455K -$10.00K -$30.32K
YoY Change 18.44% 0.0% 1.06%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.00K $0.00 -$30.51K
YoY Change 0.0% 52.55%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 $27.00K
YoY Change -100.0% 170.0%
NET CHANGE
Cash From Operating Activities -10.00K 0.000 -$30.51K
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000 $27.00K
Net Change In Cash -10.00K 0.000 -$3.509K
YoY Change -200.0% -64.91%
FREE CASH FLOW
Cash From Operating Activities -$10.00K $0.00 -$30.51K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Assets Current
AssetsCurrent
671 USD
CY2019Q3 us-gaap Assets
Assets
671 USD
CY2020Q3 us-gaap Interest Payable Current
InterestPayableCurrent
11044 USD
CY2019Q3 us-gaap Interest Payable Current
InterestPayableCurrent
6238 USD
CY2020Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
105801 USD
CY2019Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
80101 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
123327 USD
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
90642 USD
CY2020Q3 us-gaap Liabilities
Liabilities
123327 USD
CY2019Q3 us-gaap Liabilities
Liabilities
90642 USD
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
1799 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
145750 USD
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
145750 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31124 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30317 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-31124 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-26813 USD
CY2020 us-gaap Interest Expense
InterestExpense
4806 USD
CY2019 us-gaap Interest Expense
InterestExpense
3504 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4806 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3504 USD
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17990000 shares
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
671 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6482 USD
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4303 USD
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2020Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17990000 shares
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237520 USD
CY2020 us-gaap Professional Fees
ProfessionalFees
24594 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1724 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
26318 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
26813 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-26318 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-30317 USD
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17990000 shares
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17990000 shares
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-59654 USD
CY2019 us-gaap Profit Loss
ProfitLoss
-30317 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-89971 USD
CY2020 us-gaap Profit Loss
ProfitLoss
-31124 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-121095 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-30317 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2179 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3696 USD
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
4806 USD
CY2019 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3504 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24139 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30509 USD
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
25700 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25700 USD
CY2020 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1561 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
671 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268644 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-121095 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2232 USD
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1799 USD
CY2020Q3 us-gaap Assets
Assets
2232 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
3174 USD
CY2019 us-gaap Professional Fees
ProfessionalFees
25212 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1601 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-89971 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
671 USD
CY2019 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
27000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27000 USD
CY2019 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3509 USD
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4180 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2232 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
671 USD
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company’s results of operations and financial position at July 31, 2020. The full extent of the future impacts of COVID-19 on the Company’s operations is uncertain. A prolonged outbreak could have a material adverse impact on the Company’s ability to identify and/or consummate an acceptable merger or acquisition transaction.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents and related party payables that it will likely incur in the near future. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company’s management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.</p>
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
21 pure
CY2020Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
-268644 USD
CY2019Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
-237520 USD
CY2020 pnht Effective Tax Rate
EffectiveTaxRate
21%
CY2019 pnht Effective Tax Rate
EffectiveTaxRate
21%
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
56415 USD
CY2019Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49879 USD
CY2020Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-56415 USD
CY2019Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-49879 USD
CY2020Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2019Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2020 pnht Ownership Changes Annual Limitation For Net Operation Loss Carryforwards
OwnershipChangesAnnualLimitationForNetOperationLossCarryforwards
50 pure

Files In Submission

Name View Source Status
0001640334-20-002680-index-headers.html Edgar Link pending
0001640334-20-002680-index.html Edgar Link pending
0001640334-20-002680.txt Edgar Link pending
0001640334-20-002680-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pnht-20200731.xsd Edgar Link pending
pnht-20200731_cal.xml Edgar Link unprocessable
pnht-20200731_def.xml Edgar Link unprocessable
pnht-20200731_lab.xml Edgar Link unprocessable
pnht-20200731_pre.xml Edgar Link unprocessable
pnht_10k.htm Edgar Link pending
pnht_10k_htm.xml Edgar Link completed
pnht_ex311.htm Edgar Link pending
pnht_ex312.htm Edgar Link pending
pnht_ex321.htm Edgar Link pending
pnht_ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending